Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.
Immun Inflamm Dis
; 9(4): 1197-1208, 2021 12.
Article
in English
| MEDLINE | ID: covidwho-1340260
ABSTRACT
OBJECTIVE:
To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID-19 treatment.METHODS:
A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle-Ottawa scale were used to assess the quality of included studies. Meta-analysis was performed using RevMan 5.3.RESULTS:
Sixteen studies were met the inclusion criteria. No significant difference was observed between arbidol and non-antiviral treatment groups neither for primary outcomes, including the negative rate of PCR (NR-PCR) on Day 7 (risk ratio [RR] 0.94; 95% confidence interval (CI) 0.78-1.14) and Day 14 (RR 1.10; 95% CI 0.96-1.25), and PCR negative conversion time (PCR-NCT; mean difference [MD] 0.74; 95% CI -0.87 to 2.34), nor secondary outcomes (p > .05). However, arbidol was associated with higher adverse events (RR 2.24; 95% CI 1.06-4.73). Compared with lopinavir/ritonavir, arbidol showed better efficacy for primary outcomes (p < .05). Adding arbidol to lopinavir/ritonavir also led to better efficacy in terms of NR-PCR on Day 7 and PCR-NCT (p < .05). There was no significant difference between arbidol and chloroquine in primary outcomes (p > .05). No remarkable therapeutic effect was observed between arbidol and other agents (p > .05).CONCLUSION:
The present meta-analysis showed no significant benefit of using arbidol compared with non-antiviral treatment or other therapeutic agents against COVID-19 disease. High-quality studies are needed to establish the efficacy and safety of arbidol for COVID-19.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
/
Systematic review/Meta Analysis
Limits:
Humans
Language:
English
Journal:
Immun Inflamm Dis
Year:
2021
Document Type:
Article
Affiliation country:
Iid3.502
Similar
MEDLINE
...
LILACS
LIS